<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580317</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZY008-CTN</org_study_id>
    <nct_id>NCT03580317</nct_id>
  </id_info>
  <brief_title>Electroacupuncture Therapy for Change of Pain in Classical Trigeminal Neuralgia</brief_title>
  <official_title>Electroacupuncture Therapy for Change of Pain in Classical Trigeminal Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiaxing TCM Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Chinese Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The classical trigeminal neuralgia (CTN) is a common neuropathic pain in clinic by recurrent
      attacks of chronic sharp pain in the distribution of neuropathy branches of trigeminal
      neuralgia. With the lack of appropriate drug and surgery, acupuncture played a role in
      analgesia with its effective and few side effects. The study is designed to observe the
      therapeutic effect and safety of electroacupuncture (EA) in the treatment of CTN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 120 subjects with CTN who met the inclusion criteria will be included in the
      study. The subjects will be randomly divided into EA+ Carbamazepine group, EA+placebo group,
      sham EA+Carbamazepine group and sham EA+placebo group. The indexes of main outcome evaluation
      are 1)Intensity of pain (Evaluation of the pain by VAS with 0-10 points) and 2)Brief
      introduction of 2-week pain. The indexes of secondary outcome evaluation are 1) Brief Pain
      Inventory-Facial scale(BPI-Facial); 2) Patient Global Impression of Change(PGIC); 3)
      Short-Form McGill Pain Questionnaire; 4) Short- Form 36 Questionnaire. This study will
      evaluate whether EA has the advantage over carbamazepine in the immediate effect, long-term
      effect and post effect of the analgesia in CTN. At the same time, the study also will
      demonstrate whether EA has a synergistic effect with carbamazepine on the treatment of CTN,
      or even whether EA has an alternative effect on carbamazepine. Furthermore, we will establish
      a standardized, effective and convenient therapy program of EA to promote according to the
      results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Intensity of Pain at 6 months</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 3 months, 6 months</time_frame>
    <description>Evaluation of the pain by VAS with 0-10 points which that 0 means painless and 10 means very painful.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Brief introduction of 2-week pain</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 3 months, 6 months</time_frame>
    <description>According to a verifiable diary card which is recorded the subjects' pain symptoms in 24 hours every day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory-Facial scale(BPI-Facial)</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 3 months, 6 months</time_frame>
    <description>This instrument is composed of 18 items on a 1-point scale (0-10). 4 questions center on pain intensity, 7 questions deal with the interference of pain with general life activities and the remaining 7 questions deal with the interference of pain with face-specific activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change(PGIC)</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 3 months, 6 months</time_frame>
    <description>This index will record the general change impression of pain for CTN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 3 months, 6 months</time_frame>
    <description>The pain rating index has 2 subscales: these words or items are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate and 3 = severe. There's also one item for present pain intensity and one item for a 10cm visual analogue scale for average pain. This version includes 7 additional symptoms related to neuropathic pain, for a total of 22 items with 0-10 numerical response options.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form 36 Questionnaire</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks, 3 months, 6 months</time_frame>
    <description>The scale includes: 1.Physical Functioning (PF).2.Physical function (RP).3.Body Pain (BP).4.General Health (GH).5.Vitality.6.Social Functioning (SF)7.Role-emotional (RE).8.Mental Health (MH).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>EA + Carbamazepine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EA + Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham EA+ Carbamazepine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham EA+ Placebo Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EA+ Carbamazepine</intervention_name>
    <description>Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.
Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily.</description>
    <arm_group_label>EA + Carbamazepine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EA+Placebo</intervention_name>
    <description>In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.</description>
    <arm_group_label>EA + Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham EA+Carbamazepine</intervention_name>
    <description>Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).
The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.
The dosage and frequency of oral carbamazepine tablets are same as above part.</description>
    <arm_group_label>Sham EA+ Carbamazepine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham EA+Placebo</intervention_name>
    <description>The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.</description>
    <arm_group_label>Sham EA+ Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Paroxysm pain involving branches of the 2nd and/or 3rd branch of trigeminal nerve.

          2. The visual analogue score(VAS) baseline score ≥5, have a attack more than 3 times a
             day, at least 4 days a week.

          3. 18 years ≤ age ≤ 80 years.

          4. Clear consciousness, have the ability of pain perception and resolution, can complete
             the basic communication.

          5. Signed informed consent and volunteered to participate in this study.

        Exclusion Criteria:

          1. Those patients with epilepsy, head injury or other related neurological diseases.

          2. Patients with serious heart, liver, kidney damage or cognitive impairment, aphasia,
             mental disorders, or unable to cooperate with the treatment.

          3. Combined with hypertension but poor control.

          4. Severe depressive with definitive diagnosis recently.

          5. Pregnant and lactating patients.

          6. Installing pacemakers.

          7. For any other reason that is not suitable for the treatment of EA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianqiao Fang, Ph.D,M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Chinese Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianqiao Fang, Ph.D,M.D</last_name>
    <phone>86-13606707532</phone>
    <email>fangjianqiao7532@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Sun, Ph.D</last_name>
    <phone>86-13429610268</phone>
    <email>sunjing0268@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Third affiliated hospital of Zhejiang Chinese Medical university</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyu Li</last_name>
      <phone>86-15017541803</phone>
      <email>752616172@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Montano N, Conforti G, Di Bonaventura R, Meglio M, Fernandez E, Papacci F. Advances in diagnosis and treatment of trigeminal neuralgia. Ther Clin Risk Manag. 2015 Feb 24;11:289-99. doi: 10.2147/TCRM.S37592. eCollection 2015. Review.</citation>
    <PMID>25750533</PMID>
  </reference>
  <reference>
    <citation>van Kleef M, van Genderen WE, Narouze S, Nurmikko TJ, van Zundert J, Geurts JW, Mekhail N; World Institute of Medicine. 1. Trigeminal neuralgia. Pain Pract. 2009 Jul-Aug;9(4):252-9. doi: 10.1111/j.1533-2500.2009.00298.x.</citation>
    <PMID>19619267</PMID>
  </reference>
  <reference>
    <citation>Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014 Apr 10;(4):CD005451. doi: 10.1002/14651858.CD005451.pub3. Review.</citation>
    <PMID>24719027</PMID>
  </reference>
  <reference>
    <citation>Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968 Aug;19(2):129-36.</citation>
    <PMID>4877400</PMID>
  </reference>
  <reference>
    <citation>Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005451. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD005451.</citation>
    <PMID>16034977</PMID>
  </reference>
  <reference>
    <citation>Zhang R, Lao L, Ren K, Berman BM. Mechanisms of acupuncture-electroacupuncture on persistent pain. Anesthesiology. 2014 Feb;120(2):482-503. doi: 10.1097/ALN.0000000000000101. Review.</citation>
    <PMID>24322588</PMID>
  </reference>
  <reference>
    <citation>Wu CH, Lv ZT, Zhao Y, Gao Y, Li JQ, Gao F, Meng XF, Tian B, Shi J, Pan HL, Li M. Electroacupuncture improves thermal and mechanical sensitivities in a rat model of postherpetic neuralgia. Mol Pain. 2013 Apr 3;9:18. doi: 10.1186/1744-8069-9-18.</citation>
    <PMID>23551937</PMID>
  </reference>
  <reference>
    <citation>Aranha MF, Müller CE, Gavião MB. Pain intensity and cervical range of motion in women with myofascial pain treated with acupuncture and electroacupuncture: a double-blinded, randomized clinical trial. Braz J Phys Ther. 2015 Jan-Feb;19(1):34-43. doi: 10.1590/bjpt-rbf.2014.0066. Epub 2014 Nov 28.</citation>
    <PMID>25714602</PMID>
  </reference>
  <reference>
    <citation>Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.</citation>
    <PMID>14979299</PMID>
  </reference>
  <reference>
    <citation>Truini A, Galeotti F, Cruccu G. New insight into trigeminal neuralgia. J Headache Pain. 2005 Sep;6(4):237-9. Review.</citation>
    <PMID>16362674</PMID>
  </reference>
  <reference>
    <citation>Cruccu G, Biasiotta A, Galeotti F, Iannetti GD, Innocenti P, Romaniello A, Truini A. Diagnosis of trigeminal neuralgia: a new appraisal based on clinical and neurophysiological findings. Suppl Clin Neurophysiol. 2006;58:171-86.</citation>
    <PMID>16623330</PMID>
  </reference>
  <reference>
    <citation>Chen GQ, Wang XS, Wang L, Zheng JP. Arterial compression of nerve is the primary cause of trigeminal neuralgia. Neurol Sci. 2014 Jan;35(1):61-6. doi: 10.1007/s10072-013-1518-2. Epub 2013 Aug 21.</citation>
    <PMID>23963805</PMID>
  </reference>
  <reference>
    <citation>Jia DZ, Li G. Bioresonance hypothesis: a new mechanism on the pathogenesis of trigeminal neuralgia. Med Hypotheses. 2010 Mar;74(3):505-7. doi: 10.1016/j.mehy.2009.09.056. Epub 2009 Nov 8.</citation>
    <PMID>19900765</PMID>
  </reference>
  <reference>
    <citation>Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain. 2002 Jan-Feb;18(1):4-13. Review.</citation>
    <PMID>11803297</PMID>
  </reference>
  <reference>
    <citation>Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ. 2014 Feb 17;348:g474. doi: 10.1136/bmj.g474. Review.</citation>
    <PMID>24534115</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Chinese Medical University</investigator_affiliation>
    <investigator_full_name>Jianqiao Fang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Classical trigeminal neuralgia</keyword>
  <keyword>Electroacupuncture</keyword>
  <keyword>Randomized controlled clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigeminal Neuralgia</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03580317/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03580317/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

